Cholesteryl ester transfer protein (CETP) is a major determinant of plasma levels of high-density lipoprotein-cholesterol (HDL-C) in humans. The anti-atherogenic effect of lowering CETP levels is dependent not only on HDL-C levels but also on a metabolic background of increased lowdensity lipoprotein or very-low-density lipoprotein. Here we investigated the effects of JTT-705, a chemical inhibitor of CETP, on the development of atherosclerosis in Japanese white rabbits fed on a high cholesterol diet. After 4 weeks on a diet of 0.25 % cholesterol-containing chow, 100 mg/kg (low dose) or 300 mg/kg (high dose) JTT-705 was given, and the animals were monitored at weeks 0, 4, 8 and 12. Aortic atherosclerotic lesions were determined at the end of this period. JTT-705 induced a significant increase in HDL-C in the high-dose group [from 21p3 to 50p7 mg/dl (meanpS.E.M.) ; P 0.0001] compared with the control group (from 21p2 to 27p2 mg/dl). The atheromatous area was 60p9 % in the high-dose group and 58p9 % in the control group. Moreover, correlation analysis showed that triacylglycerol and non-HDL-C levels had a direct relationship with the development of atherosclerosis, but CETP activity and HDL-C levels did not. Thus the CETP inhibitor JTT-705 alone did not have an anti-atherogenic effect in our rabbit model, of severe hypercholesterolaemia suggesting a relatively minor effect of HDL-elevating therapy as compared with decreases in non-HDL-C (or triacylglycerol) levels in patients with severe hypercholesterolaemia, such as familial hypercholesterolaemia.
INTRODUCTION
Most prospective epidemiological studies have found an inverse correlation between levels of high-density lipoprotein (HDL) and the incidence of atherosclerotic cardiovascular disease, i.e. plasma HDL is a negative risk factor for atherosclerosis. Cholesteryl ester transfer protein (CETP) is a hydrophobic plasma glycoprotein which mediates the transfer and exchange of cholesteryl ester (CE) and triacylglycerol (TG) between plasma lipoproteins, and plays an important role in HDL-CE and apolipoprotein A-I catabolism [1] . CETP also promotes reverse cholesterol transport (RCT), by which peripheral cell cholesterol can be returned to the liver for catabolism [2] .
In case studies of human genetic deficiency and epidemiological studies, subjects with genetic CETP deficiency and higher levels of HDL-cholesterol (HDL-C) ( 80 mg\dl) generally have a low prevalence of coronary heart disease (CHD) [3, 4] . However, CETP deficiency caused by the D442G mutation, associated with low-to-intermediate HDL-C levels ( 60 mg\dl) resulted in an increased incidence of CHD [5] . In addition, TG levels also influence the atherogenicity of CETP deficiency. In subjects with hypertriglyceridaemia, CETP deficiency due to the I405V mutation was associated with increased incidence of CHD [6] . These studies suggest that CETP deficiency combined with lower HDL-C or higher TG levels may have a proatherogenic effect. Furthermore, the effect of increased HDL-C levels caused by CETP deficiency is insufficient to prevent CHD in patients with familial hypercholesterolaemia [7] .
Although the role of CETP in the development of atherosclerosis is controversial, CETP has been widely considered as a therapeutic target, as human CETP deficiency results in markedly elevated HDL levels. Some studies also support the hypothesis that elevating HDL by decreasing CETP mass or activity is beneficial in atherosclerosis.
In three reports of CETP lowering using cholesterolfed rabbits [8] [9] [10] , different concentrations of cholesterol in chow diet were used, and this produced various plasma cholesterol levels in rabbits. In a CETP vaccine study, hypercholesterolaemia (plasma cholesterol 932 mg\dl) was induced with a 0.25 % cholesterol diet, and an antiatherogenic effect of the CETP vaccine was proven [9] . However, CETP antisense oligonucleotides [8] and the chemical compound JTT-705 [10] protected against atherosclerosis in mildly hypercholesterolaemic rabbits fed on diets containing 0.3 % and 0.2 % cholesterol respectively (plasma cholesterol concentrations of 300 and 129 mg\dl respectively). In the present study, by increasing the amount of cholesterol in chow diet, we investigate the effects of the CETP inhibitor JTT-705 on aortic atherosclerosis in the metabolic background of severe hypercholesterolaemia.
MATERIALS AND METHODS

Materials
JTT-705 was obtained from Japan Tobacco Inc. (Tokyo, Japan). The CETP activity kit was from Roar Biomedical Inc. The Nescauto HDL kit, TG kit and total cholesterol kit were from Azwell Inc. (Osaka, Japan).
Animals
A total of 30 male Japanese white rabbits (Sla : JW) weighing 1.5-1.9 kg and 5 weeks of age were used in the experiment. (Six rabbits in each group were used in CETP antisense research, 12 rabbits in each group were analysed in the CETP vaccine study, and 10 rabbits in each group were tested in the previous JTT-705 study [8] [9] [10] .) All animals were housed individually and had free access to water. The animals were fed on a standard rabbit chow diet supplemented with 0.25 % (w\w) cholesterol for 4 weeks (50 g : kg −" : day −" ) and were then divided into three groups. Cholesterol (0.25 %)-containing chow was fed to the control group (n l 10), cholesterol chow supplemented with 0.25 % JTT-705 (100 mg\kg) was fed to the low-dose group (n l 10) and cholesterol chow supplemented with 0.75 % JTT-705 (300 mg\kg) was fed to the high-dose group (n l 10) (all 50 g : kg −" : day −" ). Blood samples were withdrawn from ear veins. Body weight was recorded at the times indicated. At week 8, according to the increase in body weight, the amount of food was increased to 120 g : rabbit −" : day −" . Two rabbits in the low-dose group died during the experimental period. The study protocol was approved by the committee of the Institute for Experimental Animals, Kanazawa University, Faculty of Medicine.
Assay for CETP activity
CETP activity was estimated from the rate of transfer of fluorescently labelled CE between synthetic HDL and human very-low-density lipoprotein (VLDL) using a CETP Diagnescent Kit (Diagnescent Technologies). NBD [N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)] linoleate was used as a tracer CE. Incubation was carried out at 37 mC for 3 h, then the reaction was stopped by chilling on ice. An aliquot of 2 µl of 10-fold diluted plasma was incubated with 3 µl of synthetic HDL, 5 µl of VLDL (cholesterol 52 mg\dl) and 140 µl of reaction buffer (10 mM Tris, 150 mM NaCl, 2 mM EDTA, pH 7.4). The fluorescence was measured with an excitation wavelength of 465 nm and an emission wavelength of 535 nm in a 96-well plate using Biolumin 960 (Molecular Dynamics Japan). According to specific fluorescent activity, transfer activity was expressed in nmol : h −" : ml −" .
Assay for lipids
Plasma lipids were determined by enzymic methods in plasma samples. Plasma HDL-C and HDL-TG were determined enzymically in the supernatant after heparincalcium precipitation. Non-HDL-C levels were calculated by subtracting HDL-C from total cholesterol.
Determination of platelet-activating factor acetylhydrolase (PAF-AH)
PAF-AH activity was determined using a PAF-AH assay kit (Cayman Chemical Co., Ann Arbor, MI, U.S.A.). The substrate was 2-thio-PAF.
Measurement of lipoprotein lipase (LPL) and hepatic lipase activities in post-heparin plasma
Blood was collected from rabbits 5 min after intravenous injection of heparin (100 i.u.\kg body weight). LPL activity in post-heparin plasma was measured as described previously using glycerol tri[1-"%C]oleate as the substrate [11] . Post-heparin LPL activity was calculated by subtracting hepatic lipase activity measured in the presence of 1 mol\l NaCl from total post-heparin lipase activity measured in the absence of 1 mol\l NaCl.
Lesion analysis
At the end of the experimental period, the animals were anaesthetized using intravenous sodium pentobarbital and exsanguinated. The aortas were dissected from the heart to bifurcation and gently rinsed with PBS, and the periaortic tissue was carefully removed. The aortas were immersed in phosphate buffer containing 10 % formalin (pH 7.2) and stored overnight at 4 mC. The cleaned aortas were opened longitudinally. The tissue was stained with Sudan III and IV to visualize areas of fat deposition and digitally photographed for analysis. The lesion area of the aortic arch was quantified by Image Gauge V3.41 software (Fuji Photo Film Co. Ltd, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using StatView 5.0 software. Values are given as meanspS.E.M. Repeatedmeasures ANOVA was used to compare the three experimental groups and study periods, followed by Student's t test with Bonferroni's correction. A corrected value of P 0.05 was considered significant. Rank correlations were assessed by Spearman's coefficient. The coefficient of variation for repeated measurement of the atheromatous area was 8% (n l 3), and those for analytical measurements of lipids and enzymic activities were 5 % and 10 % respectively.
RESULTS
CETP activity
As shown in Table 1 , after 4 weeks on a 0.25 % cholesterol diet, the basal levels of CETP activity were not different among the three groups of rabbits. CETP activity was increased by 2.8-fold in the control group from week 0 to week 12 ( Figure 1 ). In the low-dose JTT-705 group, CETP activity increased by 26 %. In contrast, a decrease in CETP activity observed in the high-dose JTT-705 group was minimal (14 %). At week 12, the levels of CETP activity were decreased by 55 % (P 0.001) and 69 % (P 0.001) in the low-dose and high-dose groups respectively compared with that in the control group.
Plasma lipids
The plasma cholesterol levels of the three groups did not change significantly during the experimental period ( Figure 1 , Table 1 ). In accordance with the decreases in CETP activity, the levels of HDL-C and TG were increased in the JTT-705-treated groups compared with the controls, in both a time-and dose-dependent manner. Rank correlation analysis showed an inverse correlation between CETP activity and HDL-C level ; however, there were no correlations between CETP activity and TG. A significant increase in HDL-C in the high-dose JTT-705 group was observed at week 4 (P 0.01). The HDL-C concentration plateaued after week 8 in the three groups. At week 8, HDL-C levels were 1.2-fold higher in the low-dose JTT-705 group (35p8 mg\dl) and 2-fold higher in the high-dose JTT-705 group (58p9 mg\dl) than that in the controls (29p4 mg\dl). At week 12, the levels of TG were increased by 19 % in the low-dose group (102p12 mg\dl) and by 110 % in the highdose group (182p52 mg\dl ; P l 0.05) compared with controls (86p15 mg\dl). The levels of HDL-TG were decreased by 15 % in the low-dose group and by 25 % (P l 0.002) in the high-dose group compared with controls. Non-HDL-C levels increased over time. At the end of the experiment, although non-HDL-C levels in the high-dose JTT-705 group were lower than those in the control group, there were no statistically significant differences among the three groups. However, the atherogenic index was significantly decreased by 54 % (P l 0.030) in the high-dose JTT-705 group compared with the control group.
Body weight, LPL and hepatic lipase activities in post-heparin plasma, and plasma PAF-AH Body weight increased slightly by about 30 % during the experimental period in all three groups. At week 12, the body weight of the high-dose JTT-705 group was slightly higher than that of the controls (P l 0.049). The levels of LPL and hepatic lipase activity were not different among the three groups. Although the levels of PAF-AH increased from 0 to 12 weeks, they did not differ among the three groups at any time point.
Atheromatous area
The aortic lesion area per rabbit did not differ significantly among the three groups (Table 1 ). Spearman's rank correlation analysis showed that atheromatous area was significantly correlated with non-HDL-C, TG and cholesterol during the experimental period, but not with 
Duration of treatment is shown in weeks (W).
HDL-C or CETP activity (Table 2 ). Individual changes in serum non-HDL-C and TG levels and aortic lesion area are shown in Figures 2 and 3 .
DISCUSSION
CETP activity is one of the determinants of plasma HDL-C levels in humans. JTT-705 is a chemical inhibitor of CETP, which may inactivate CETP via binding to Cys-13 [10] . The present study confirmed that inclusion of the compound JTT-705 in the diet resulted in an elevation of plasma HDL-C by specific inhibition of plasma CETP activity in experimental rabbits, similar to that seen in subjects with heterozygous CETP deficiency. However, the atheromatous area was not correlated with HDL-C levels or CETP, but was correlated with TG and non-HDL-C levels ( Table 2 ). The lack of an inverse correlation between CETP activity and lesion area indicates that CETP activity did not play a role in the development of atherosclerosis in our rabbit model with severe hypercholesterolaemia. There were some differences in study design between the present study and a seminal report by Okamoto et al. [10] . First, in our study, rabbits were fed on a diet containing a higher concentration of cholesterol (0.25 %) ; extremely high levels of atherogenic lipoprotein were present in the plasma of these animals in comparison with HDL levels, inducing severe hypercholesterolaemia (Table 3 ). This subtle change in dietary cholesterol between 0.2 % and 0.25 % could produce a large difference in plasma cholesterol levels [12] . Non-HDL-C levels over 0-12 weeks showed a direct relationship with atheromatous area (Table 2 ). The high levels of non-HDL-C could induce the development of athersclerosis (Figure 2) , although there was concurrent increase in HDL-C in rabbits treated with JTT-705. A clinical study showed a similar result in subjects with familial hypercholesterolaemia with or without CETP deficiency [7] . Although HDL-C levels (60 mg\dl) in subjects with familial hypercholesterolaemia with CETP deficiency were higher than those (46 mg\dl) in subjects with familial hypercholesterolaemia without CETP deficiency, the effect of increased HDL-C levels was insufficient to prevent CHD [7] . At lower levels of non-HDL-C, it is possible that elevations in HDL due to CETP inhibition may contribute more to protection from atherosclerosis. This concept is supported by Sugano et al. [8] . In that study, the non-HDL-C level was shown to be moderate (284 mg\dl) in control rabbits fed on a 0.3 % cholesterol diet ; suppression of CETP expression by antisense oligodeoxynucleotides inhibited the development of atherosclerosis and induced a remarkable decrease in non-HDL-C levels. Secondly, the drug treatment period was longer in the study of Okamoto et al. [10] than in the present study (6 and 3 months respectively). It is possible that a longer treatment period results in greater atherosclerosis regression mediated by HDL.
The protective effect of HDL against atherosclerosis is believed to be due to the ability of HDL to facilitate RCT from peripheral tissues to the liver for removal or reutilization. In this process, HDL plays two roles : (1) as an acceptor of cholesterol and (2) as a reservoir of CE for re-utilization. Overexpression of lecithin : cholesterol acyltransferase (LCAT) in transgenic animals increased the generation of large HDL particles with altered lipid and protein composition [13, 14] . HDL efflux studies indicated that HDLs were good acceptors of cholesterol efflux in transgenic mice. However, marked protection against atherosclerosis was shown in LCAT transgenic rabbits, but the opposite results were found in LCAT transgenic mice. The presence of the CETPmediated transfer of CE from HDL to apolipoprotein B-containing lipoprotein in rabbits, but not in mice, may account for these differences in atherogenicity of LCAT overexpression. Similarly, increased cholesterol efflux activity of HDL obtained from JTT-705-fed rabbits was demonstrated [15] . The CETP-mediated CE transfer pathway was disrupted by JTT-705, indicating that the use of a CETP inhibitor may result in dysfunctional HDL which allows efficient efflux of membrane cholesterol in vivo but is unable to deliver cholesterol to the liver.
Besides activation of RCT, HDL exerts antiatherogenic effects by other antioxidative, anti-platelet aggregation, anti-thrombotic or anti-inflammatory mechanisms. Inactivation of CETP activity by JTT-705 results in elevated HDL-CE levels and decreased RCT to the liver, indicating that other functions of HDL may be more important than RCT for its anti-atherogenic action.
An unexpected result found in our present study was that administration of 0.75 % JTT-705 in the diet elevated not only HDL-C but also TG levels ( Figure 1 ). As Table 2 and Figure 3 show, the elevated TG showed a direct relationship with atheromatous area, which may explain why there was no effect on atherosclerosis despite low CETP activity and high HDL levels. An epidemiological study showed that CETP deficiency increased CHD in subjects with hypertriglyceridaemia [6] . A similar finding was made with animal models. In mice with hypertriglyceridaemia caused by overexpression of the human apolipoprotein CIII transgene, CETP expression inhibited the development of early atherosclerotic lesions [16] . Thus the CETP inhibitor JTT-705 might not be useful in patients with hypertriglyceridaemia.
This phenomenon of elevated TG has not been reported in other studies of CETP inhibition in cholesterol-fed rabbits. Hepatic lipase activity is high in human and rats, and very low in rabbits [17, 18] . In our studies, LPL and hepatic lipase activity were determined, but there were no differences among groups (Table 1) . JTT-705 may elevate TG via stimulated TG synthesis in rabbits ; however, this appears to be the case only in severe hypercholesterolaemia, since JTT-705 at 0.75 % did not change TG levels in rabbits fed on a 0.2 % cholesterol diet or in human clinical trials [10, 19] . Another possibility to explain the increase in TG levels would be decreased susceptibility to lipolysis due to abnormal composition of VLDL\intermediate-density lipoprotein (IDL). HDL-TG levels were decreased in the high-dose JTT-705 group compared with controls ( Table 1 ), suggesting that TG transfer from VLDL\IDL to HDL was inhibited and that TG accumulated in VLDL\IDL. In view of the prospect of therapy for atherosclerotic vascular disease using JTT-705, it will be important to monitor the changes in plasma TG, especially in subjects with low hepatic lipase activity.
In conclusion, the CETP inhibitor JTT-705 alone did not have an anti-atherogenic effect in our rabbit model of severe hypercholesterolaemia, suggesting a relatively minor effect of HDL-elevating therapy as compared with decreases in non-HDL-C (or TG) levels in patients with severe hypercholesterolaemia, such as familial hypercholesterolaemia. It may be worth trying combined therapy of a statin and a CETP inhibitor in such patients.
